类风湿关节炎相关间质性肺病:2007年至2020年间的发病率、患病率及相关药物处方
基于德国BARMER全国理赔数据(2007—2020年),在类风湿关节炎(RA)人群中,间质性肺病(ILD)年患病率为1.7%—2.2%,年发病率为0.13%—0.21%且保持稳定;ILD在血清阳性RA、男性和老年人中更常见。糖皮质激素、csDMARD和非甾体抗炎药使用下降,bDMARD上升;专科诊疗与疾病特异性治疗相关,但镇痛药和阿片类药物需求持续较高。
要点
- RA-ILD年患病率1.7%—2.2%,2013年以来略有下降;年发病率0.13%—0.21%,保持稳定。
- ILD在血清阳性RA、男性和老年人中更常见,2020年平均年龄72岁。
- 糖皮质激素(84%降至68%)、csDMARD(83%降至55%)和非甾体抗炎药(62%降至38%)使用下降,bDMARD(16%升至24%)上升。
核心结论
- RA-ILD罕见且主要影响老年人;未观察到发病率趋势,但治疗策略有所扩大;需要专科诊疗以提供疾病特异性治疗;持续较高的镇痛药和阿片需求表明这些患者存在未满足的需求。
研究设计与样本
- 基于德国BARMER全国理赔数据(2007—2020年)的索赔数据分析;RA-ILD通过诊断编码、改善病情抗风湿药(DMARD)处方和肺部诊断识别;ILD相对于首次诊断年份被判定为 incident 或 prevalent。
主要发现
- 在所有RA患者中(2007年40 686例至2020年85 175例),每年1.7%—2.2%患有ILD,自2013年以来略有下降。
- incident ILD每年为0.13%—0.21%,随时间保持稳定。
- ILD在血清阳性RA、男性和老年人中更常见(2020年平均年龄72岁)。
- 糖皮质激素(84%降至68%)、csDMARD(83%降至55%)和非甾体抗炎药(62%降至38%)使用下降,而bDMARD(16%升至24%)上升。
- 2020年,7%接受tsDMARD,3%接受抗纤维化药,44%接受镇痛药,30%接受阿片类药物。
关键数值与推荐
- RA-ILD年患病率1.7%—2.2%,年发病率0.13%—0.21%。
- 2020年药物使用:糖皮质激素68%,csDMARD 55%,非甾体抗炎药38%,bDMARD 24%,tsDMARD 7%,抗纤维化药3%,镇痛药44%,阿片类药物30%。
- 阿片使用:无专科参与39%,风湿科诊疗32%,呼吸科诊疗21%。
临床怎么用
- 原文结论指出需要专科诊疗以提供疾病特异性治疗;有风湿科医生参与时DMARD治疗更常见,有呼吸科医生参与时抗纤维化药更常见。
- 原文指出持续较高的镇痛药和阿片需求表明这些患者存在未满足的需求。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate prevalence, incidence and medication of interstitial lung disease (ILD) among German individuals with rheumatoid arthritis (RA). METHODS: Nationwide BARMER claims data from 2007 to 2020 were used. RA-ILD was identified by diagnosis codes, prescription of disease-modifying antirheumatic drugs (DMARDs) and lung diagnostics. ILD was assigned as incident or prevalent relative to the year of the first diagnosis. We identified prescriptions of glucocorticoids, conventional synthetic (cs), biological (b) and targeted synthetic (ts)DMARDs, antifibrotics and rheumatology and/or pulmonology care. RESULTS: Among all persons with RA (40 686 in 2007 to 85 175 in 2020), 1.7%-2.2%/year had ILD with a slight decline since 2013. Incident ILD was 0.13%-0.21% per year and remained stable over time. ILD was more common in seropositive RA, in men and in the elderly (mean age 72 years in 2020). Glucocorticoids (84% to 68%), csDMARD (83% to 55%) and non-steroidal anti-inflammatory drug use (62% to 38%) declined, while bDMARDs (16% to 24%) rose. In 2020, 7% received tsDMARDs, 3% antifibrotics, 44% analgesics and 30% opioids. DMARD therapy was more common if a rheumatologist was involved and antifibrotics if a pulmonologist was involved. Opioid use was highest if no specialist was involved (39%) but also common in rheumatology care (32%) and less frequent in pulmonology care (21%). CONCLUSIONS: RA-ILD is rare and mainly affects elderly persons. No trend in incidence was observed but treatment strategies have enlarged. Specialist care is necessary to provide disease-specific therapies. The continuing high analgesic and opioid demand shows unmet needs in these patients.
引用
- Albrecht K, Strangfeld A, Marschall U, et al. Interstitial lung disease in rheumatoid arthritis: incidence, prevalence and related drug prescriptions between 2007 and 2020. RMD Open. 2023. PMID: 36669830. doi:10.1136/rmdopen-2022-002777
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。